Please assess the completion status of the following clinical trial:

Trial Title: Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Healthy volunteers:~1. Must be 18 years of age or older.~2. Must have no known medical problems and have had a full medical exam within 6 months of the study.~3. Must understand and voluntarily have signed an Informed Consent after its contents have been fully explained.~4. Women of child bearing potential (as defined as women who are not post menopausal for 12 months or who have had no previous surgical sterilization).~5. Men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 30 days after the last dose.~Cancer subjects:~1. Greater than 18 years-old at the time of radiotracer administration~2. Provides written informed consent~3. Diagnosed with advanced non-small cell lung cancer (NSCLC), breast cancer, pancreatic cancer and glioblastoma multiforme (GBM); patients will undergo bevacizumab or Cyberknife therapy~4. Able to remain still for duration of each imaging procedure (about one hour)~Exclusion Criteria~1. Less than 18 years-old at the time of radiotracer administration~2. Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healty Volunteers (Type: OTHER): Normal volunteers to receive 5 to 14 mCi F18-FPPRGD2 by intravenous (IV) injection.
- Breast Cancer (Type: EXPERIMENTAL): Breast cancer patients to receive 4 to 11 mCi F18-FPPRGD2 by IV injection.
- Glioblastoma Multiform (brain) (Type: EXPERIMENTAL): Glioblastoma multiform patients to receive 5 to14 mCi F18-FPPRGD2 by IV injection.
- Lung Cancer (Type: EXPERIMENTAL): Lung cancer patients to receive X to XX mCi F18-FPPRGD2 by IV injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).